Terns Pharmaceuticals, Inc. - Common Stock (TERN)

Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) experienced a significant downturn, plummeting over 10% in premarket trading and continuing to slide throughout the day, following the release of late-stage study results for its highly anticipated oral weight-loss drug, orforglipron. While the drug met its primary

Eli Lilly's obesity drug data misses targets, boosting shares of Novo Nordisk, Viking, Structure, and Terns amid promising trial updates.

Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention.

Terns has a modest market cap of less than $800 million, and its possible upside could be massive.

Terns Pharmaceuticals just proved that it's competitive in the weight loss field.

Getting in on the ground floor sounds like a great idea, but not if the building ends up crumbling.

This biotech's data suggests that it could have an advantage in its target market.

Terns Pharmaceuticals announced promising Phase 1 trial results for TERN-601, showing significant weight loss in obese and overweight adults, with up to 4.9% placebo-adjusted mean weight loss at the highest dose.

The race to develop the next big obesity treatment is on with leaders Lilly and Novo trying to keep their top slots.

TERN stock results show that Terns Pharma beat analyst estimates for earnings per share the second quarter of 2024.

Biotech stocks are a high risk, high reward investment and these three biotechs offer significant upside potential.

At least one of the pair has a credible shot at finding a home in the market.

Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry.